• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Executive Officer Tangney Jeffrey was granted 168,154 shares and covered exercise/tax liability with 7,990 shares, increasing direct ownership by 8% to 2,257,048 units (SEC Form 4)

    5/19/25 8:26:28 PM ET
    $DOCS
    EDP Services
    Technology
    Get the next $DOCS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Tangney Jeffrey

    (Last) (First) (Middle)
    DOXIMITY, INC.
    500 THIRD STREET

    (Street)
    SAN FRANCISCO CA 94107

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Doximity, Inc. [ DOCS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    04/24/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Class A Common Stock 04/24/2025 A 168,154(1) A $0 2,265,038 D
    Class A Common Stock 05/15/2025 F 7,990(2) D $59.5 2,257,048(3) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents shares of Class A Common Stock underlying performance-based restricted stock units ("PSUs") granted on October 24, 2024. Following the Compensation Committee's certification of the applicable financial performance results for the fiscal year ended March 31, 2025, 100% of the PSUs shall vest on May 15, 2027, subject to the Reporting Person's continued service to the Issuer through such vesting date. Each PSU represents a contingent right to receive one share of the Issuer's Class A Common Stock.
    2. Represents shares of Class A Common Stock withheld by the Issuer in satisfaction of tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. Such withholding is mandated by an election of the Issuer made in advance and does not represent a discretionary trade by the Reporting Person.
    3. Includes 209 shares of Class A Common Stock received as a pro rata distribution in kind, for no consideration, on March 5, 2025 from Emergence Capital Opportunity I, L.P., of which the Reporting Person is a non-managing limited partner. Such pro rata distribution in kind was made in accordance with the exemption afforded by Rule 16a-9 of the Securities Exchange Act of 1934, as amended.
    Remarks:
    /s/ Jennifer Chaloemtiarana, Attorney-in-Fact 05/19/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $DOCS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DOCS

    DatePrice TargetRatingAnalyst
    2/7/2025$31.00 → $78.00Neutral → Overweight
    Piper Sandler
    2/7/2025$60.00 → $90.00Market Perform → Outperform
    Leerink Partners
    12/20/2024$55.00Equal-Weight
    Stephens
    12/4/2024$55.00Neutral
    Mizuho
    11/15/2024$58.00Neutral
    Goldman
    11/14/2024$33.00 → $53.00Underweight → Equal-Weight
    Morgan Stanley
    11/13/2024$40.00 → $60.00Buy → Hold
    Canaccord Genuity
    11/8/2024$19.00 → $41.00Underweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $DOCS
    Leadership Updates

    Live Leadership Updates

    See more
    • Mendaera Closes $73M Series B Financing to Scale Robotics and AI Across Mainstream Medical Procedures

      With its first-of-its-kind platform, Mendaera is pioneering a new category in medical robotics Mendaera, Inc., a Silicon Valley-based healthcare technology company developing a handheld robotic interventional platform, announced today the close of $73 million in Series B funding led by Threshold Ventures, with participation from investors including Lux Capital, PFM Health Sciences, and Fred Moll (founder of Intuitive Surgical and Auris Health). The financing will further Mendaera's efforts to scale robotics and AI across mainstream medical procedures. The healthcare system is facing an increasing supply and demand crisis, where the ability to consistently deliver high-quality care to pati

      9/26/24 6:05:00 AM ET
      $DOCS
      $RELY
      $LVGO
      EDP Services
      Technology
      Business Services
      Consumer Discretionary
    • Doximity Appoints Phoebe Yang to Its Board of Directors

      Experienced director and executive brings health system and cloud expertise SAN FRANCISCO, Aug. 4, 2022 /PRNewswire/ -- Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced the appointment of Phoebe L. Yang to its Board of Directors. Ms. Yang has been General Manager at Amazon Web Services, Healthcare, and a member of the board of directors for CommonSpirit Health, one of the largest U.S. health systems. Ms. Yang is a long-time member of the Council on Foreign Relations, and has served as an appointee in two Presidential Administrations. In 2021, she was named one of Modern Healthcare's Top 100 Most Influential People in Healthcare and one

      8/4/22 4:02:00 PM ET
      $DOCS
      EDP Services
      Technology

    $DOCS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Doximity Inc.

      SC 13G/A - Doximity, Inc. (0001516513) (Subject)

      11/14/24 5:22:01 PM ET
      $DOCS
      EDP Services
      Technology
    • SEC Form SC 13G filed by Doximity Inc.

      SC 13G - Doximity, Inc. (0001516513) (Subject)

      11/14/24 11:42:53 AM ET
      $DOCS
      EDP Services
      Technology
    • SEC Form SC 13G filed by Doximity Inc.

      SC 13G - Doximity, Inc. (0001516513) (Subject)

      11/12/24 9:55:17 AM ET
      $DOCS
      EDP Services
      Technology

    $DOCS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Doximity to Present at the William Blair 45th Annual Growth Stock Conference

      Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced that Jeff Tangney, co-founder and CEO, will present at the William Blair 45th Annual Growth Stock Conference on Tuesday, June 3, 2025 at 4:40 p.m. Central Time. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 80% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and research, manage their care

      5/21/25 4:01:00 PM ET
      $DOCS
      EDP Services
      Technology
    • Doximity Announces Fourth Quarter and Fiscal Year 2025 Financial Results

      Q4 total revenues of $138.3 million, up 17% year-over-year Q4 operating cash flow of $98.5 million, up 54% year-over-year Q4 free cash flow of $97.0 million, up 56% year-over-year Fiscal year 2025 total revenues of $570.4 million, up 20% year-over-year Fiscal year 2025 operating cash flow of $273.3 million, up 48% year-over-year Fiscal year 2025 free cash flow of $266.7 million, up 50% year-over-year Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2025 fourth quarter and fiscal year ended March 31, 2025. "We closed out fiscal 2025 on a high note, with record engagement, strong profits, and 20% annual revenue g

      5/15/25 4:01:00 PM ET
      $DOCS
      EDP Services
      Technology
    • Doximity to Release Fiscal 2025 Fourth Quarter and Full Year Results on May 15, 2025

      Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal fourth quarter and full year ended March 31, 2025 after market close on May 15, 2025. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ before the call. A webcast replay will be available on the website following the call. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members

      4/24/25 4:01:00 PM ET
      $DOCS
      EDP Services
      Technology

    $DOCS
    Financials

    Live finance-specific insights

    See more
    • Doximity Announces Fourth Quarter and Fiscal Year 2025 Financial Results

      Q4 total revenues of $138.3 million, up 17% year-over-year Q4 operating cash flow of $98.5 million, up 54% year-over-year Q4 free cash flow of $97.0 million, up 56% year-over-year Fiscal year 2025 total revenues of $570.4 million, up 20% year-over-year Fiscal year 2025 operating cash flow of $273.3 million, up 48% year-over-year Fiscal year 2025 free cash flow of $266.7 million, up 50% year-over-year Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2025 fourth quarter and fiscal year ended March 31, 2025. "We closed out fiscal 2025 on a high note, with record engagement, strong profits, and 20% annual revenue g

      5/15/25 4:01:00 PM ET
      $DOCS
      EDP Services
      Technology
    • Doximity to Release Fiscal 2025 Fourth Quarter and Full Year Results on May 15, 2025

      Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal fourth quarter and full year ended March 31, 2025 after market close on May 15, 2025. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ before the call. A webcast replay will be available on the website following the call. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members

      4/24/25 4:01:00 PM ET
      $DOCS
      EDP Services
      Technology
    • Doximity Announces Fiscal 2025 Third Quarter Financial Results

      Total revenues of $168.6 million, up 25% year-over-year Net income growth of 57% and adjusted EBITDA growth of 39% year-over-year Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2025 third quarter ended December 31, 2024. "We're proud to deliver another quarter of record engagement in Q3, with over 610,000 unique providers using our clinical workflow tools," said Jeff Tangney, co-founder and CEO of Doximity. "Our AI tools grew the fastest last quarter, up 60% over the prior quarter, while our newsfeed surpassed more than one million unique providers." Fiscal 2025 Third Quarter Financial Highlights All com

      2/6/25 4:01:00 PM ET
      $DOCS
      EDP Services
      Technology

    $DOCS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $DOCS
    SEC Filings

    See more

    $DOCS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Director Cabral Timothy S converted options into 10,000 shares and sold $505,796 worth of shares (10,000 units at $50.58) (SEC Form 4)

      4 - Doximity, Inc. (0001516513) (Issuer)

      5/27/25 4:24:22 PM ET
      $DOCS
      EDP Services
      Technology
    • Chief Financial Officer Bryson Anna covered exercise/tax liability with 5,120 shares, decreasing direct ownership by 1% to 352,045 units (SEC Form 4)

      4 - Doximity, Inc. (0001516513) (Issuer)

      5/19/25 8:31:21 PM ET
      $DOCS
      EDP Services
      Technology
    • Chief Executive Officer Tangney Jeffrey was granted 168,154 shares and covered exercise/tax liability with 7,990 shares, increasing direct ownership by 8% to 2,257,048 units (SEC Form 4)

      4 - Doximity, Inc. (0001516513) (Issuer)

      5/19/25 8:26:28 PM ET
      $DOCS
      EDP Services
      Technology
    • SEC Form S-8 filed by Doximity Inc.

      S-8 - Doximity, Inc. (0001516513) (Filer)

      5/20/25 5:03:47 PM ET
      $DOCS
      EDP Services
      Technology
    • SEC Form 10-K filed by Doximity Inc.

      10-K - Doximity, Inc. (0001516513) (Filer)

      5/20/25 4:09:38 PM ET
      $DOCS
      EDP Services
      Technology
    • Doximity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Doximity, Inc. (0001516513) (Filer)

      5/15/25 4:04:25 PM ET
      $DOCS
      EDP Services
      Technology
    • Doximity upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Doximity from Neutral to Overweight and set a new price target of $78.00 from $31.00 previously

      2/7/25 9:03:46 AM ET
      $DOCS
      EDP Services
      Technology
    • Doximity upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Doximity from Market Perform to Outperform and set a new price target of $90.00 from $60.00 previously

      2/7/25 6:59:36 AM ET
      $DOCS
      EDP Services
      Technology
    • Stephens initiated coverage on Doximity with a new price target

      Stephens initiated coverage of Doximity with a rating of Equal-Weight and set a new price target of $55.00

      12/20/24 7:32:05 AM ET
      $DOCS
      EDP Services
      Technology